An inherited disorder of lymphocyte apoptosis: The autoimmune lymphoproliferative syndrome

Annals of Internal Medicine

Volumn 130, Issue 7, 1999, Pages 591-601

  Straus, Moderator Stephen E ^a   Sneller, Michael ^a   Lenardo, Michael J ^a   Puck, Jennifer M ^b   Strober, Warren ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOKINE; DEXAMETHASONE; FAS ANTIGEN; IMMUNOGLOBULIN; PREDNISONE;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC RISK; HISTOPATHOLOGY; HUMAN; HYPERSPLENISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; LYMPHADENOPATHY; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 0345059209     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-7-199904060-00020     Document Type: Conference Paper

References (68)

1. Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992;90:334-41.
2. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-9.
3. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
4. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335:1643-9.
5. Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N, et al. Clinical, immunological, and pathological consequences of Fasdeficient conditions. Lancet. 1996;348:719-23.
6. Sneller MC, Wang J, Dale JK, Strober W, Middleton LA, Choi Y, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341-8.
7. Bettinardi A, Brugnoni D, Quiròs-Roldan E, Malagoli A, La Grutta S, Correra A, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome a molecular and immunological analysis. Blood. 1997;89:902-9.
8. Infante AJ, Britton HA, DeNapoli T, Middleton LA, Lenardo MJ, Jackson CE, et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome due to a Fas mutation that impairs lymphocyte apoptosis. J Pediatr. 1998;133:629-33.
9. Wilson C. Some cases showing hereditary enlargement of the spleen. Transactions of the Clinical Society. 1890;23:16-172.
10. Randall DL, Reiquam WC, Githens JH, Robinson A. Familial myeloproliferative disease. Am J Dis Child. 1965;110:479-500.
11. Darte JM, McClure PD, Saunders EF, Weber J, Donohue WL. Congenital lymphoid hyperplasia with persistent hyperlymphocytosis. N Engl J Med. 1971;284:431-2.
12. Holiman JL, Madge GE. A familial disorder characterized by hepatosplenomegaly presenting as "preleukemia." Va Med Mon. 1971;98:644-8.
13. Rao LM, Shahidi NT, Opitz JM. Hereditary splenomegaly with hypersplenism. Clin Genet. 1974;5:379-86.
14. Hess AF. The blood and blood vessels in hemophilia and other hemorrhagic diseases. Arch Intern Med. 1916;17:203-20.
15. Dameshek W, Schwartz SO. Hemolysins as the cause of clinical and expermental hemolytic anemias. With particular reference to the nature of spherocytosis and increased fragility. Am J Med Sci 1938;196:769-92.
16. Evans RS, Takahashi K, Duane RT, Payne R, Liu CK. Primary thrombocytopenic purpura and acquired hemolytic anemia. Evidence for a common etiology. Ann Intern Med. 1951;87:48-65.
17. Hennemann VH, Krause H. Chronische Trombozytopenie (Morbus Werlhof) und erworbene hämolytische Anämie bei zwei Schwestern. [Chronic thrombocytopenia (Werlhof's disease) and acquired hemoloytic anemia in two sisters.] Dtsche Med Wochenschr. 1964;89:1161-6.
18. Harms D, Sachs V. Familial chronic thrombocytopenia with platelet autoantibodies. Acta Haematol. 1965;34:30-5.
19. Seip M, Harboe M, Cyvin K. Chronic autoimmune hemolytic anemia in childhood with cold antibodies, aplastic crises, and familial occurrence. Acta Paediatr Scand. 1969;58:275-80.
20. Dacie J. The Haemolytic Anemias. Vol. 3. New York: Churchill Livingstone; 1992.
21. Dale DC. Lymphadenopathy and lymphoproliferative disorders. Immunology and Allergy Clinics of North America. 1993;13:359-69.
22. Canale VC, Smith CH, Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70:891-9.
23. Weisdorf SA, Krivit W. Paucity of splenic germinal centers: a new and unique splenomegaly syndrome including dysfunctional immune system. Clin Immunol Immunopathol. 1982;23:492-500.
24. Horowitz SD, Borcherding W, Hong R. Autoimmune hemolytic anemia as a manifestation of T-suppressor-cell deficiency. Clin Immunol Immunopathol. 1984;33:313-23.
25. McKinley R, Kwan YL, Lam-po-Tang PR. Familial splenomegaly syndrome with reduced circulating T helper cells and splenic germinal centre hypoplasia. Br J Haematol. 1987;67:393-6.
26. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol. 1985;37:269-390.
27. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol. 1991;9: 243-69.
28. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989;245:301-5.
29. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314-8.
30. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol. 1994;24:3057-62.
31. Lim MS, Straus SE, Dale JK, Fleisher TA, Stetler-Stevenson M, Strober W, et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol. 1998;153:1541-50.
32. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-5.
33. Mountz JD, Smith HR, Wilder RL, Reeves JP, Steinberg AD. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol. 1987;138:157-63.
34. Gutierrez JC, Andreu JL, Revilla Y, Vinuela E, Martinez C. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature. 1990;346:271-4.
35. Lenardo MJ. Fas and the art of lymphocyte maintenance. J Exp Med. 1996; 183:721-4.
36. Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Ann Rev Immunol. 1992;10:267-93.
37. Lenardo MJ. The molecular regulation of lymphocyte apoptosis. Semin Immunol. 1997;9:1-5.
38. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959-66.
39. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-56.
40. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348-51.
41. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995; 14:5579-88.
42. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1- and TNF receptor-induced cell death. Cell. 1996;85:803-15.
43. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry HA, Wong WW, et al. Human ICE/CED-3 protease nomenclature [Letter]. Cell. 1996;87:171.
44. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature. 1996;384:638-41.
45. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fasmediated apoptosis. Nature. 1995;375:78-81.
46. Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, et al. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature. 1995;375:81-3.
47. Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science. 1996;274:990-2.
48. Chinnaiyan AM, Dixit VM. Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. Semin Immunol. 1997;9:69-76.
49. Dianzani U, Bragardo M, DiFranco D, Alliaudi C, Scagni P, Buonfiglio D, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood. 1997;89: 2871-9.
50. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98:1107-13.
51. Fuss IJ, Strober W, Dale JK, Fritz S, Pearlstein GR, Puck JM, et al. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humor autoimmunity. J Immunol. 1997;158:1912-8.
52. Sarris AH, Kliche KO, Peethambaram PP, Witzig T, Andreeff M, Cabanillas F. lnterleukin-10 as a prognostic factor for Hodgkin's disease treated with ABVD: results from MD Anderson and Mayo Clinic [Abstract]. Blood. 1997;90:335a.
53. + T cell receptor (TCR)alpha/beta double-negative T cells express CD28 and respond to costimulation with phorbol myristate acetate and antibodies to CD28 and the TCR. J Immunol. 1993;151:597-609.
54. Giese T, Davidson WF. Chronic treatment of C3H-lpr/lpr and C3H gld/gld mice with anti-CD8 monoclonal antibody prevents the accumulation of double negative T cells but not autoantibody production. J Immunol. 1994;152: 2000-10.
55. Ferrante P, Fusi ML, Sarasella M, Caputo D, Biasin M, Trabattoni D, et al. Cytokine production and surface marker expression in acute and stable multiple sclerosis altered IL-12 production and augmented signaling lymphocyte activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol. 1998;160:1514-21.
56. + lamina propria (LP) lymphocyte secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-70.
57. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med. 1998;187:537-46.
58. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281-90.
59. Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Ohtsuka K, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 1998;41:838-44.
60. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine. 1998;10:148-53.
61. Segal R, Bermas BL, Dayan M, Kalush F, Shearer G, Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/ T helper cell 2-type cytokines in disease. J Immunol. 1997;158:3009-16.
62. + T cells, increased TH2-type cytokines, mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol. 1993;92: 213-34.
63. Tanaka H, Nagai H, Maeda Y. Effect of anti-IL-4 and anti-IL-5 antibodies on allergy airway hyperresponsiveness in mice. Life Sci. 1994;62:PL169-74.
64. Moore KW, O'Garra A, de Waal Malefyt R, Veiera P, Mosmann T. Interleukin-10. Annu Rev Immunol. 1993;11:165-90.
65. Mongan A, Ramdahin S, Warrington RJ. Interleukin-10 response abnormalities in systemic lupus erythematosus. Scand J Immunol. 1997;46:406-12.
66. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bc1-2 protein. J Clin Invest. 1994;93:424-8.
67. Li L, Krajewski S, Reed JC, Choi YS. The apoptosis and proliferation of SAC-activated B cells by IL-10 are associated with changes in Bcl-2, Bcl-xL, and Mc1-1 expression. Cell Immunol. 1997;178:33-41.
68. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology. 1997;92:1-5.